financetom
Business
financetom
/
Business
/
Greenbrier Fiscal Q3 Earnings, Revenue Increase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Greenbrier Fiscal Q3 Earnings, Revenue Increase
Jul 1, 2025 1:56 PM

04:35 PM EDT, 07/01/2025 (MT Newswires) -- Greenbrier (GBX) reported fiscal Q3 earnings late Tuesday of $1.86 per diluted share, up from $1.06 a year earlier.

Two analysts polled by FactSet expected $0.99.

Revenue for the quarter ended May 31 was $842.7 million, up from $820.2 million a year earlier.

Two analysts surveyed by FactSet expected $785.7 million.

The company reiterated its fiscal 2025 revenue guidance of $3.15 billion to $3.35 billion.

Two analysts polled by FactSet expect $3.22 billion.

Shares were up over 10% in after-hours activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Jfrog Insider Sold Shares Worth $314,464, According to a Recent SEC Filing
Jfrog Insider Sold Shares Worth $314,464, According to a Recent SEC Filing
Sep 5, 2024
05:57 PM EDT, 09/03/2024 (MT Newswires) -- Tali Notman, Chief Revenue Officer, on September 03, 2024, sold 11,621 shares in Jfrog ( FROG ) for $314,464. Following the Form 4 filing with the SEC, Notman has control over a total of 547,413 shares of the company, with 547,413 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1800667/000141588924022707/xslF345X05/form4-09032024_090957.xml Price: 26.97, Change: +0.63, Percent Change:...
Enliven Therapeutics Insider Sold Shares Worth $269,841, According to a Recent SEC Filing
Enliven Therapeutics Insider Sold Shares Worth $269,841, According to a Recent SEC Filing
Sep 5, 2024
05:49 PM EDT, 09/03/2024 (MT Newswires) -- Joseph P Lyssikatos, Chief Scientific Officer, on August 29, 2024, sold 12,000 shares in Enliven Therapeutics ( ELVN ) for $269,841. Following the Form 4 filing with the SEC, Lyssikatos has control over a total of 1,077,936 shares of the company, with 1,077,936 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1672619/000141588924022704/xslF345X05/form4-09032024_090954.xml ...
Appfolio Insider Sold Shares Worth $903,261, According to a Recent SEC Filing
Appfolio Insider Sold Shares Worth $903,261, According to a Recent SEC Filing
Sep 5, 2024
05:42 PM EDT, 09/03/2024 (MT Newswires) -- Maurice J Duca, 10% Owner, on August 29, 2024, sold 3,875 shares in Appfolio ( APPF ) for $903,261. Following the Form 4 filing with the SEC, Duca has control over a total of 220,790 shares of the company, with 19,122 shares held directly and 201,668 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1433195/000141588924022701/xslF345X05/form4-09032024_090900.xml ...
Royalty Pharma, Ascendis Pharma Unit Have $150 Million Royalty Funding Agreement
Royalty Pharma, Ascendis Pharma Unit Have $150 Million Royalty Funding Agreement
Sep 5, 2024
05:49 PM EDT, 09/03/2024 (MT Newswires) -- Royalty Pharma plc ( RPRX ) entered into a $150 million capped synthetic royalty funding agreement with an Ascendis Pharma ( ASND ) unit. The Ascendis Pharma Bone Diseases subsidiary will get an upfront payment of $150 million in exchange for a 3% royalty on US net sales of Yorvipath, a hormone replacement...
Copyright 2023-2026 - www.financetom.com All Rights Reserved